Insider Transactions Highlight Nuvalent's Market Activity Nuvalent's CEO recently sold shares worth $2.05 million, while also exercising options to acquire additional shares. This activity comes as the company continues to advance its clinical trials, including pivotal data releases in 2025. Analysts remain optimistic, with price targets up to $137, reflecting confidence in its growth potential.23